

Glucose 40%

Newborn use only

2024

| | |
|--------------------------|---|
| Alert | 40% glucose, on average, raises blood glucose by 0.4 mmol/L (95% CI -0.14–0.94) ² and should not be used alone in the treatment of moderate to severe hypoglycaemia. This can be a nurse-initiated medication according to the local hospital guideline. DO NOT squirt gel directly into the baby's mouth. as this can cause choking |
| Indication | Prevention and treatment of mild hypoglycaemia in neonates ≥35 weeks' gestation and <48 hours of life ^{1,2} |
| Action | Glucose, a simple carbohydrate, in a concentrated aqueous gel solution can be administered by direct application to mucosal surfaces of the mouth, including buccal and lingual surfaces. Absorption from these sites may allow rapid access to the circulation. Some proportion of the dose may be swallowed and absorbed from the gastrointestinal tract. ² |
| Drug type | Glucose 40%. |
| Trade name | SugarBabies Gel (Biomed, New Zealand) 40% glucose in Water for Injection (Baxter compounded solution. Product ID GLR.082) Other preparations (e.g. Glutose15 Oral Glucose Gel)– Refer to special comments section. |
| Presentation | SugarBabies Gel -ORAL Dextrose 40% Gel syringe (Biomed, New Zealand): Each 2.5 mL syringe contains Glucose (1 g), citric acid monohydrate, carmellose sodium, water. (TGA Listing 354150) 40% glucose in Water for Injection: Supplied in 2 mL oral syringe by Baxter (glucose syringe product GLR.082) – Discontinued. |
| Dose | 0.5 mL/kg/dose (200 mg/kg/dose). ³ Doses can be repeated as per the local hospital guidelines. 1 mL/kg/dose (400 mg/kg/dose) as a single dose has also been used. ⁵ |
| Dose adjustment | Not applicable. |
| Maximum dose | Not more than 1.5 mL/kg. If no response, alternate measures to treat hypoglycaemia should be instituted. |
| Route | ORAL |
| Preparation | |
| Administration | This can be a nurse-initiated medication according to the local hospital guideline. Dextrose 40% Gel: <ol style="list-style-type: none"> 1. Wearing a clean glove, gently dry the infant's buccal mucosa with gauze. NOTE: If using tube, draw up required dose of gel slowly in an oral-only 5 mL syringe. 2. Dispense one-half of the dose from oral syringe onto gloved finger. 3. Massage into the buccal mucosa of one cheek. DO NOT SQUIRT DIRECTLY INTO BABY'S MOUTH. 4. Repeat with remaining half-dose inside the other cheek. 5. Large doses may be divided into 4 equal amounts and given alternating between cheeks. 6. Commence breastfeeding or administer expressed breast milk or formula. 7. Discard the unused portion of the gel. Glucose 40% solution (Baxter) <ol style="list-style-type: none"> 1. Wearing a clean glove, gently dry the infant's buccal mucosa with gauze. 2. Instill the prescribed dose slowly into the side of the mouth onto the buccal mucosa and massage it in with a gloved finger.⁶ DO NOT SQUIRT DIRECTLY INTO BABY'S MOUTH. 3. Commence breastfeeding or administer expressed breast milk or formula. 4. Discard the unused portion. |
| Monitoring | Measure blood glucose 30 minutes after administration and subsequent management is as per the hospital guideline. |
| Contraindications | No information. |
| Precautions | <35 weeks gestation; infants at risk of aspiration or in whom feeds are contraindicated. |
| Drug interactions | No information. |
| Adverse reactions | Risk of aspiration if the gel is squirted directly into mouth. |
| Overdose | No specific recommendation. |
| Compatibility | No information. |
| Incompatibility | No information. |
| Stability | Single use product. Discard unused portion. |
| Storage | All preparations: Room Temperature <25°C |
| Special comments | Other preparation available in Australia: Glutose15 Oral Glucose Gel: 15 g of glucose / 37.5 g tube. 200 mg of glucose gel 40% is equivalent to 0.5 mL. Lemon flavoured. Contains citric acid monohydrate, water, |

| | |
|------------------------|--|
| | dextrose, glycerin, methylparaben, potassium sorbate, propylparaben, carboxymethylcellulose, sodium citrate. SugarBabies Gel is the recommended option. Manufacturer does not recommend Glucose15 Gel under 2 years of age. |
| Evidence | <p><u>Prevention of neonatal hypoglycaemia</u></p> <p>Hegarty et al, in a systematic review, assessed the effectiveness and safety of oral dextrose gel in preventing hypoglycaemia among newborn infants at risk of hypoglycaemia and in reducing long-term neurodevelopmental impairment. They included one trial comparing oral dextrose gel versus placebo in 416 infants at risk of hypoglycaemia, most of whom were infants of diabetic mothers and were treated on the postnatal ward. Oral dextrose gel prophylaxis (any dose) was associated with reduced risk of hypoglycaemia compared with placebo (risk ratio (RR) 0.76, 95% confidence interval (CI) 0.62 to 0.94). There were no statistically significant differences in the number of adverse events, separation from mother for treatment of hypoglycaemia, exclusive breastfeeding at discharge or breastfeeding at six weeks postpartum. They concluded that oral dextrose gel reduced the risk of neonatal hypoglycaemia in at-risk infants with no statistically significant differences in the number of adverse events or in risk of separation of infant from mother for treatment of hypoglycaemia [LOE 1, GOR A]</p> <p><u>Treatment of neonatal hypoglycaemia</u></p> <p>Weston et al, in a systematic review, assessed the effectiveness of dextrose gel in correcting hypoglycaemia and in reducing long-term neurodevelopmental impairment in neonates at risk of hypoglycaemia.² They included two trials involving 312 infants. They found no significant difference between dextrose gel and placebo gel for major neurosensory disability at two-year follow-up (risk ratio (RR) 6.27, 95% confidence interval (CI) 0.77 to 51.03; one trial, n = 184; quality of evidence very low). Dextrose gel compared with placebo or no gel did not alter the need for intravenous treatment for hypoglycaemia (typical RR 0.78, 95% CI 0.46 to 1.32; two trials, 312 infants; quality of evidence very low). Infants treated with dextrose gel were less likely to be separated from their mothers for treatment of hypoglycaemia (RR 0.54, 95% CI 0.31 to 0.93; one trial, 237 infants; quality of evidence moderate) and were more likely to be exclusively breastfed after discharge (RR 1.10, 95% CI 1.01 to 1.18; one trial, 237 infants; quality of evidence moderate). Treatment of infants with neonatal hypoglycaemia with 40% dextrose gel reduces the incidence of mother-infant separation for treatment and increases the likelihood of full breast feeding after discharge compared with placebo gel. No excess adverse effects have been reported during the neonatal period or at two years' corrected age. Oral dextrose gel has not been compared to supplementary feeding with human milk or formula. Oral dextrose gel may be considered as first-line treatment for infants with neonatal hypoglycaemia. [LOE 1, GOR A]</p> |
| Practice points | |
| References | <ol style="list-style-type: none"> Hegarty JE, Harding JE, Crowther CA, Brown J, Alsweiler J. Oral dextrose gel to prevent hypoglycaemia in at-risk neonates. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012152. DOI: 10.1002/14651858.CD012152.pub2. Weston PJ, Harris DL, Battin M, Brown J, Hegarty JE, Harding JE. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD011027. DOI: 10.1002/14651858.CD011027.pub2. Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> 2013;382(9910):2077–83. Harris D, Alsweiler J, Ansell J, Gamble G, Thompson B, Wouldes T, et al. Outcome at 2 years after dextrose gel treatment for neonatal hypoglycaemia: follow-up of a randomized trial. <i>Journal of Pediatrics</i> 2016;170:54–9. Troughton KEV, Corrigan NP, Tait RME. Hypostop gel in the treatment of neonatal hypoglycaemia: a randomised controlled trial. <i>Archives of Disease in Childhood</i> 2000;82 (Suppl 1):A30. |

| VERSION/NUMBER | DATE |
|----------------------------|------------|
| Original 1.0 | 20/07/2018 |
| Version 2.0 | 20/06/2019 |
| Current 3.0 | 4/03/2024 |
| Current 3.0 (Minor errata) | 13/06/2024 |
| REVIEW | 4/03/2029 |

Authors Contribution for the current version

| | |
|------------------------------------|--|
| Author/s | Srinivas Bolisetty |
| Evidence Review (original version) | David Osborn |
| Pharmacy Review | Rebecca O'Grady, Thao Tran |
| Nursing Review | Eszter Jozsa, Bryony Malloy |
| ANMF Group contributors | Nilkant Phad, Bhavesh Mehta, Rebecca Barzegar, Martin Kluckow, Mohammad Irfan Azeem, Michelle Jenkins, Cindy Chen, Helen Huynh, Susanah Brew, Simarjit Kaur, Stephanie Halena, Benjamin Emerson-Parker, Renae Gengaroli, Kerryn Houghton |
| Final editing | Srinivas Bolisetty |
| Electronic version | Thao Tran, Helen Huynh, Cindy Chen, Ian Callander |
| Facilitator | Srinivas Bolisetty |

Citation for the current version

Bolisetty S, Osborn D, O'Grady R, Tran T, Phad N, Mehta B, Barzegar R, Kluckow M, Azeem MI, Jozsa E, Malloy B, Jenkins M, Chen C, Huynh H, Brew S, Kaur S, Halena S, Emerson-Parker B, Gengaroli R, Houghton K, Callander I. Glucose 40%. Consensus formulary by the Australasian Neonatal Medicines Formulary group. Version 3. Dated 4 March 2023. www.anmfonline.org